Cargando…
Clinical Features and Multiplatform Molecular Analysis Assist in Understanding Patient Response to Anti-PD-1/PD-L1 in Renal Cell Carcinoma
SIMPLE SUMMARY: Immune checkpoint inhibitor (ICI) therapy has proven effective for many cancer patients, but predicting which patients with renal cell carcinoma (RCC) will respond has been challenging. We analyzed clinical characteristics and molecular parameters of a cohort of patients with RCC tre...
Autores principales: | Shiuan, Eileen, Reddy, Anupama, Dudzinski, Stephanie O., Lim, Aaron R., Sugiura, Ayaka, Hongo, Rachel, Young, Kirsten, Liu, Xian-De, Smith, Christof C., O’Neal, Jamye, Dahlman, Kimberly B., McAlister, Renee, Chen, Beiru, Ruma, Kristen, Roscoe, Nathan, Bender, Jehovana, Ward, Joolz, Kim, Ju Young, Vaupel, Christine, Bordeaux, Jennifer, Ganesan, Shridar, Mayer, Tina M., Riedlinger, Gregory M., Vincent, Benjamin G., Davis, Nancy B., Haake, Scott M., Rathmell, Jeffrey C., Jonasch, Eric, Rini, Brian I., Rathmell, W. Kimryn, Beckermann, Kathryn E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004696/ https://www.ncbi.nlm.nih.gov/pubmed/33806963 http://dx.doi.org/10.3390/cancers13061475 |
Ejemplares similares
-
Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma
por: Beckermann, Kathryn E., et al.
Publicado: (2017) -
Renal cell carcinoma
por: Jonasch, Eric, et al.
Publicado: (2014) -
Modeling Clear Cell Renal Cell Carcinoma and Therapeutic Implications
por: Wolf, Melissa M., et al.
Publicado: (2020) -
OPtimal Treatment by Invoking biologic clusters in renal cell carcinoma (OPTIC RCC)
por: Beckermann, Kathryn, et al.
Publicado: (2023) -
The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy
por: Lim, Aaron R, et al.
Publicado: (2020)